Spruce Biosciences, Inc. (NASDAQ: SPRB) priced a public offering of 1,150,000 shares of its common stock at $50.00 per share, generating $60 million in gross proceeds. The offering expands the company’s cash position to a level that supports the upcoming Biologics License Application (BLA) submission and the confirmatory trial for its lead enzyme‑replacement therapy, tralesinidase alfa (TA‑ERT), for Sanfilippo Syndrome Type B (MPS IIIB).
The $60 million raise represents roughly 62% of Spruce’s market capitalization, which was about $96.7 million on the day of pricing. This proportion underscores the significance of the capital infusion relative to the company’s valuation and highlights the importance of the funding for the next regulatory milestones. Prior to this public offering, Spruce had secured a $50 million private placement in October 2025 and a $50 million loan facility with Avenue Capital in January 2026, demonstrating a consistent need for capital to advance its pipeline.
TA‑ERT has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration. The company’s acquisition of the rights to TA‑ERT from BioMarin and Allievex shifted its focus from endocrinology to rare neurological disorders, positioning the therapy as a potential first‑in‑class treatment for a disease with no approved options. The new equity raise will fund the final stages of regulatory preparation and the confirmatory trial that will be required for FDA approval.
Management has emphasized the strategic importance of the funding. CEO Javier Szwarcberg has highlighted the strength of the clinical data and the company’s progress with the FDA, while the appointment of Dale Hooks as Chief Commercial Officer signals a readiness to build commercial capabilities in anticipation of potential approval. The capital raise also provides a buffer against the cash demands of late‑stage development and the high costs associated with bringing a rare‑disease therapy to market.
The offering is part of Spruce’s broader strategy to maintain a strong cash position while pursuing a late‑stage development program. With more cash than debt and a current ratio of 5.17, the company is positioned to absorb the costs of the BLA submission and confirmatory trial without compromising its operational needs. The financing underscores the company’s commitment to advancing TA‑ERT and reflects confidence in the therapy’s potential to address an unmet medical need.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.